Literature DB >> 24090943

Liver abnormalities in pregnancy.

Nwe Ni Than1, James Neuberger.   

Abstract

Abnormalities of liver function (notably rise in alkaline phosphatase and fall in serum albumin) are common in normal pregnancy, whereas rise in serum bilirubin and aminotransferase suggest either exacerbation of underlying pre-existing liver disease, liver disease related to pregnancy or liver disease unrelated to pregnancy. Pregnant women appear to have a worse outcome when infected with Hepatitis E virus. Liver diseases associated with pregnancy include abnormalities associated hyperemesis gravidarum, acute fatty liver disease, pre-eclampsia, cholestasis of pregnancy and HELLP syndrome. Prompt investigation and diagnosis is important in ensuring a successful maternal and foetal outcome. In general, prompt delivery is the treatment of choice for acute fatty liver, pre-eclampsia and HELLP syndrome and ursodeoxycholic acid is used for cholestasis of pregnancy although it is not licenced for this indication.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute fatty liver; Cholestasis of pregnancy; HELLP syndrome; Liver disease; Pre-eclampsia; Pregnancy

Mesh:

Year:  2013        PMID: 24090943     DOI: 10.1016/j.bpg.2013.06.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  9 in total

Review 1.  Immunology of hepatic diseases during pregnancy.

Authors:  Lars Bremer; Christoph Schramm; Gisa Tiegs
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

2.  Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.

Authors:  Luc Ra Rougée; Shogo J Miyagi; Abby C Collier
Journal:  Hawaii J Med Public Health       Date:  2016-12

Review 3.  Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy.

Authors:  Sebiha Ozkan; Yasin Ceylan; Orhan Veli Ozkan; Sule Yildirim
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Maternal liver elasticity determined by acoustic radiation force impulse elastosonography in intrahepatic cholestasis of pregnancy.

Authors:  Orkun Cetin; Erbil Karaman; Harun Arslan; Ibrahim Akbudak; Recep Yildizhan; Ali Kolusari
Journal:  J Med Ultrason (2001)       Date:  2016-12-30       Impact factor: 1.314

Review 5.  Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective.

Authors:  Renée M Marchioni Beery; Haleh Vaziri; Faripour Forouhar
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

6.  Hepatic, renal and inflammatory biomarkers are positively associated with blood pressure changes in healthy pregnant women: a prospective cohort.

Authors:  Gilberto Kac; Roberta H Mendes; Dayana R Farias; Ilana Eshriqui; Fernanda Rebelo; Camila Benaim; Ana Amélia F Vilela; Natália S Lima; Wilza A F Peres; Gil F Salles
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 7.  Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).

Authors:  Xiang Kong; Yan Kong; Fangyuan Zhang; Tingting Wang; Jin Yan
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

8.  Guidelines on the management of abnormal liver blood tests.

Authors:  Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman
Journal:  Gut       Date:  2017-11-09       Impact factor: 23.059

9.  Liver Dysfunction during Pregnancy and Its Association of With Preterm Birth in China: A Prospective Cohort Study.

Authors:  Xun Zhuang; Ai-Min Cui; Qin Wang; Xiao-Yan Cheng; Yi Shen; Wei-Hua Cai; Hai-Bo Li; Sheng Zhang; Gang Qin
Journal:  EBioMedicine       Date:  2017-11-21       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.